(Total Views: 432)
Posted On: 08/26/2022 7:22:18 AM
Post# of 36541
FWIW, I have just written an email to info@olaregen.com
Here is my text, should I receive an answer, I will post it here as well:
Subject: Status on rollout of Excellagen
Dear ladies and gents,
I am a long term GNBT investor, and, as you may imagine, I currently feel devastated about the developments not just of the GNBT share value over the course of the last roughly 1,5 years, that have passed since the last GNBT investor conference call, held in May of 2021. The information presented to us back then, all sounded so upbeat and promising, including the update given by Anthony Dolisi.
Unfortunately, this May 21 CC was the last real update we received from anyone within the companies. As we all learned from his status change on LinkedIn, Joseph Moscato seems to have abandoned the GNBT ship, and so we cannot expect to hear anything further from him. So I am wondering if anyone within your company can give us an update on the planned rollout of Excellagen on a ready to be signed credit based financing deal as Anthony described during that mentioned GNBT CC. From what I recall, this rollout was supposed to generate double digit million dollar revenues within less than the first year after the launch in the first half of 2021.
GNBT shareholders are absolutely desperate to receive updates from within the company, and thus any publicly announced information from your side would be highly appreciated.
Many thanks in advance.
Best regards from Germany
Here is my text, should I receive an answer, I will post it here as well:
Subject: Status on rollout of Excellagen
Dear ladies and gents,
I am a long term GNBT investor, and, as you may imagine, I currently feel devastated about the developments not just of the GNBT share value over the course of the last roughly 1,5 years, that have passed since the last GNBT investor conference call, held in May of 2021. The information presented to us back then, all sounded so upbeat and promising, including the update given by Anthony Dolisi.
Unfortunately, this May 21 CC was the last real update we received from anyone within the companies. As we all learned from his status change on LinkedIn, Joseph Moscato seems to have abandoned the GNBT ship, and so we cannot expect to hear anything further from him. So I am wondering if anyone within your company can give us an update on the planned rollout of Excellagen on a ready to be signed credit based financing deal as Anthony described during that mentioned GNBT CC. From what I recall, this rollout was supposed to generate double digit million dollar revenues within less than the first year after the launch in the first half of 2021.
GNBT shareholders are absolutely desperate to receive updates from within the company, and thus any publicly announced information from your side would be highly appreciated.
Many thanks in advance.
Best regards from Germany
(6)
(0)Scroll down for more posts ▼
